← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

Name Funds
holding 		Growth Growth % Fund
value
OSTX icon
176
OS Therapies Inc
OSTX
$65.1M
29 0 0% $5.5M
CSBR icon
177
Champions Oncology
CSBR
$66.9M
28 +3 +12% $36.3M
PMCB icon
178
PharmaCyte Biotech
PMCB
$3.74M
28 -4 -13% $586K
RNXT icon
179
RenovoRx
RNXT
$50.5M
28 -3 -10% $9M
XAIR icon
180
Beyond Air
XAIR
$2.07M
28 0 0% $607K
APRE icon
181
Aprea Therapeutics
APRE
$7.34M
27 +5 +23% $1.9M
CLLS icon
182
Cellectis
CLLS
$113M
27 -5 -16% $28.4M
INKT icon
183
MiNK Therapeutics
INKT
$52.8M
27 +4 +17% $2.39M
KYNB icon
184
Kyntra Bio
KYNB
$22.6M
27 -5 -16% $7.54M
XLO icon
185
Xilio Therapeutics
XLO
$58.6M
27 +3 +13% $32.6M
MDXH icon
186
MDxHealth
MDXH
$60.3M
26 -25 -49% $6.79M
TIL icon
187
Instil Bio
TIL
$40.4M
26 -6 -19% $29.2M
TOVX icon
188
Theriva Biologics
TOVX
$9.63M
26 +4 +18% $496K
IMMP
189
Immutep
IMMP
$24.9M
24 0 0% $692K
PHIO icon
190
Phio Pharmaceuticals
PHIO
$11M
24 0 0% $663K
SLGL icon
191
Sol-Gel Technologies
SLGL
$228M
24 +3 +14% $98.1M
BOLT icon
192
Bolt Biotherapeutics
BOLT
$7.67M
23 -1 -4% $2.31M
IMNN icon
193
Imunon
IMNN
$5.84M
23 +4 +21% $754K
MBIO icon
194
Mustang Bio
MBIO
$2.8M
23 +1 +5% $378K
MDCX icon
195
Medicus Pharma
MDCX
$4.47M
23 +2 +10% $1.18M
BYSI icon
196
BeyondSpring
BYSI
$24.1M
22 +2 +10% $10.6M
CLDI icon
197
Calidi Biotherapeutics
CLDI
$2.26M
22 -5 -19% $89.3K
CNSY icon
198
Cerenome
CNSY
$12.8M
22 -1 -4% $2.89M
BCAB icon
199
DELISTED
BIOATLA INC
BCAB
21 -15 -42% $1.22M
INAB icon
200
IN8bio
INAB
$11.8M
21 +2 +11% $5.35M
6 7
8
9 10